A patient-driven clinicogenomic partnership for metastatic prostate cancer

A patient-driven clinicogenomic partnership for metastatic prostate cancer

Molecular profiling studies have enabled discoveries for metastatic prostate cancer (MPC) but have predominantly occurred in academic medical institutions and involved non-representative patient populations. We established the Metastatic Prostate Cancer Project (MPCproject, mpcproject.org), a patien...

Full description

Bibliographic Details
Other Authors:	Massachusetts Institute of Technology. Department of Biology
Format:	Article
Language:	English
Published:	Elsevier BV 2022
Online Access:	https://hdl.handle.net/1721.1/146862

Similar Items

Management of prostate cancer. Part 3: metastatic disease.
by: Shah, J, et al.
Published: (2006)

The oncologic role of local treatment in primary metastatic prostate cancer.
by: Ghadjar, P, et al.
Published: (2014)

Molecular subgroup of primary prostate cancer presenting with metastatic biology.
by: Walker, SM, et al.
Published: (2017)

Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer
by: Jones, RH, et al.
Published: (2023)

Radical therapy may reduce mortality in men with metastatic prostate cancer
by: Sooriakumaran, P, et al.
Published: (2014)

Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
by: Khan, O, et al.
Published: (2012)

Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate.
by: Khan, O, et al.
Published: (2012)

Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer.
by: Leversha, M, et al.
Published: (2009)

Novel signalling pathways regulating epithelial-mesenchymal transition in bone metastatic prostate cancer
by: Rao, SR
Published: (2014)

Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists' perspective
by: Tan, J, et al.
Published: (2017)

Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer
by: Adalsteinsson, Viktor A., et al.
Published: (2014)

Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy.
by: Jain, S, et al.
Published: (2017)

iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer.
by: Rehman, I, et al.
Published: (2012)

Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy
by: Wu, X, et al.
Published: (2019)

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
by: Van Cutsem, E, et al.
Published: (2016)

The role of YWHAG in metastatic cancer
by: Lee, Jeannie Xue Ting
Published: (2023)

Multi-slice DCE-MRI data using P760 distinguishes between metastatic and non-metastatic rodent prostate tumors.
by: Fan, X, et al.
Published: (2006)

Colorectal cancer liver metastatic growth depends on PAD4-driven citrullination of the extracellular matrix
by: Yuzhalin, Y, et al.
Published: (2018)

Evaluation of fatty liver in breast cancer patients and its metastatic potential
by: Ahmad, Nor Hayati
Published: (2021)

Effect of deep diaphragmatic breathing on pain in patients with metastatic gastrointestinal cancers
by: Rezaei, Maryam, et al.
Published: (2024)

Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.
by: Maughan, T, et al.
Published: (2010)

Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer
by: Rao, S, et al.
Published: (2016)

Phase I study of TNFalpha AutoVaccIne in patients with metastatic cancer.
by: Waterston, A, et al.
Published: (2005)

A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation
by: Sooriakumaran, P, et al.
Published: (2016)

Recurrent and/or metastatic thyroid cancer: therapeutic options.
by: Karavitaki, N, et al.
Published: (2002)

Re: Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study
by: Philippou, Y, et al.
Published: (2020)

Eight-plex iTRAQ analysis of variant metastatic human prostate cancer cells identifies candidate biomarkers of progression: An exploratory study.
by: Glen, A, et al.
Published: (2010)

Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease.
by: Hellawell, G, et al.
Published: (2002)

Large tumour-derived extracellular vesicles as prognostic indicators of metastatic cancer patient survival
by: Goberdhan, DCI
Published: (2022)

High OGT activity is essential for MYC-driven proliferation of prostate cancer cells
by: Itkonen, H, et al.
Published: (2019)

A meta-analysis and meta-regression of the efficacy, toxicity, and quality of life outcomes following prostate-specific membrane antigen radioligand therapy utilising lutetium-177 and actinium-225 in metastatic prostate cancer
by: Dai, Y-H, et al.
Published: (2024)

The tumor microenvironment and immune responses in prostate cancer patients
by: Kwon, JTW, et al.
Published: (2021)

Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies
by: Dillinger, T, et al.
Published: (2022)

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
by: Chi, K, et al.
Published: (2018)

SOURCE: A registry-based prediction model for overall survival in patients with metastatic oesophageal or gastric cancer
by: Van Den Boorn, HG, et al.
Published: (2019)

Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab.
by: Griffiths, R, et al.
Published: (2011)

The current status of checkpoint inhibitors in metastatic bladder cancer
by: Fahmy Ahmed, Omar Ahmed, et al.
Published: (2016)

Emerging intrinsic therapeutic targets for metastatic breast cancer
by: Li, Jiawei, et al.
Published: (2023)

How metastatic cancer cells become resistant to apoptosis
by: Zhou, Zhicai
Published: (2014)

The genomic and immune landscapes of lethal metastatic breast cancer
by: De Mattos-Arruda, L, et al.
Published: (2019)